A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF versus Adefovir Dipivoxil for the Treatment of HBeAg Positive Chronic Hepatitis B

Trial Profile

A Randomized, Double-Blind, Controlled Evaluation of Tenofovir DF versus Adefovir Dipivoxil for the Treatment of HBeAg Positive Chronic Hepatitis B

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Apr 2017

At a glance

  • Drugs Tenofovir disoproxil fumarate (Primary) ; Adefovir dipivoxil
  • Indications Hepatitis B
  • Focus Registrational; Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 17 Apr 2016 Results of presence of Bcp/Pc variants in reducing the rate of Hbsag loss in patients on long term Tenofovir therapy (n=157) presented at The International Liver Congress™ 2016
    • 22 Mar 2016 Status changed from active, no longer recruiting to completed, according to European Clinical Trials Database record.
    • 25 Nov 2015 Results regarding the evaluation of aspartate aminotransferase (AST)-to-platelet ratio index (APRI) and fibrosis index based on four factors (FIB-4) scoring systems from CHB patients enrolled in NCT00117676 and NCT00116805 published in the Journal of Hepatology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top